Persephone biosciences and ginkgo bioworks announce collaboration to develop novel therapeutics

Multi-project agreement involves engineering of anaerobic species, a critical component for microbiome medicines san diego and boston , april 12, 2022 /prnewswire/ -- persephone biosciences inc. , a synthetic biology company reimagining patient and infant health, and ginkgo bioworks  (nyse: dna), the leading horizontal platform for cell programming, today announced a collaboration to develop a novel therapeutics based on the bacterial genus bacteroides. bacteroides species are among the most common members of the microbiota of animals, especially in the gastrointestinal tract, and are likely a useful tool for stable and long-term delivery of microbial medicines.
DNA Ratings Summary
DNA Quant Ranking